Structure Therapeutics Inc.
Financials
Valuation Metrics
Structure Therapeutics Inc.'s Market Cap is $2.49B. At end of 2025 it was $4.12B. Ranked #1872 of 3,121 in US market (top 60%), #692 of 1,463 on NASDAQ (top 47%), #116 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 44%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.49B | US#1,872/3,121 Sec#116/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-215M | US—/3,121 Sec—/266 |
| Total Assets | $1.43B | US#2,287/3,121 Sec#71/266 |
| Net Assets | $1.35B | US#1,553/3,121 Sec#47/266 |
| Employees | 233 | US#2,468/3,121 Sec#124/266 |
| Value | ||
| P/B | 1.84x | US#1,127/3,121 Sec#39/266 |
| FCF Yield | -9.02% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -15.88% | US#2,440/3,121 Sec#90/266 |
| ROA | -15.09% | US#2,747/3,121 Sec#116/266 |
| Financial Health | ||
| Debt Ratio | 5.24% | US#40/3,121 Sec#14/266 |
| Total Debt | $6M | US#2,884/3,121 Sec#213/266 |
| FCF | $-224M | US#2,797/3,121 Sec#215/266 |
| Cash | $273M | US#1,488/3,121 Sec#87/266 |
| Current Ratio | 20.75x | US#117/3,121 Sec#25/266 |
| Performance | ||
| 1Y Return | 50.67% | US#426/3,121 Sec#90/266 |
| 1M Return | -35.34% | US#3,096/3,121 Sec#264/266 |
| From 52W High | -63.12% | US#2,942/3,121 Sec#239/266 |
| 1Y MDD | -62.68% | US#2,833/3,121 Sec#220/266 |
| Trading | ||
| Volume | 1,491,698 shares | US#1,636/3,121 Sec#176/266 |
| Trading Value | $52M | US#1,669/3,121 Sec#127/266 |
| Per Share | ||
| EPS | $-3.03 | US—/3,121 Sec—/266 |
| BPS | $19.06 | US#1,290/3,121 Sec#31/266 |
Company Info
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.